Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study
Authors:
- Marcus SchmidtMarcus Schmidt
- Tobias HesseTHTobias Hesse
- Oliver HoffmannOHOliver Hoffmann
- Bernhard J. HeinrichBHBernhard J. Heinrich
- Tjoung-Won Park-SimonTPTjoung-Won Park-Simon
- Eva-Maria GrischkeEGEva-Maria Grischke
- Rudolf WeideRWRudolf Weide
- Harald Müller HuesmannHHHarald Müller Huesmann
- Kerstin Lüdtke-HeckenkampKLKerstin Lüdtke-Heckenkamp
- Dorothea FischerDFDorothea Fischer
- Cosima ZemlinCZCosima Zemlin
- Matthias KögelMKMatthias Kögel
Open Access
Abstract
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safety and quality of life (QoL), in patients with advanced/metastatic BC. IRENE was an observational, single-arm, prospective, multicenter cohort study. Patients aged ≥18 years with locally advanced/metastatic BC that progressed after 1–3 prior chemotherapeutic regimens received eribulin and were monitored for new-onset or worsening EIPN. Secondary endpoints included time to disease progression, safety, and health-related QoL. In total, 108 (32.2%) out of 335 patients experienced EIPN; 18 (5.4%) experienced grade ≥3 EIPN. Median time to EIPN resolution (EIPN ended or returned to baseline) was 78.7 weeks (95% CI 77.1—not estimable). Median time to disease progression was 4.5 months (95% CI 3.9–5.5). Treatment-emergent adverse events (TEAEs) occurred in 322 (96.1%) patients; serious TEAEs occurred in 185 (55.2%) patients. Incidence and resolution rates of EIPN were comparable with existing evidence from previous trials. TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.Keywords
All Related Versions
Funding Information
- Eisai GmbH, Frankfurt, Germany
This publication has 8 references indexed in Scilit:
- Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort StudyThe Oncologist, 2023
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational studyBreast Cancer, 2018
- Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysisOncotarget, 2017
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneJournal of Clinical Oncology, 2015
- Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathyBreast Cancer Research and Treatment, 2013
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011